NCT04802733 - Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

May 18, 2023

Study Completion Date

June 10, 2024

Conditions

Advanced Parkinson's Disease

Interventions

BIOLOGICAL

MSK-DA01

MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.

DEVICE

MSK-DA01 Cell Delivery Device

A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.

Trial Locations (3)

10065

Weill Cornell Medical College, New York

92868

University of California Irvine, Orange

M5T 2S8

Toronto Western Hospital, Toronto